Fajriyah, Nanda Nur and Setiadi, Antonius Adji Prayitno (2025) Theraupetic Management of Patients with Evans Syndrome: Narrative Review (Tata Laksana Terapi Pasien dengan Sindrom Evans: Kajian Naratif). Journal Pharmaceutical And Sciences, 8 (3). ISSN 2656-3088 (Submitted)
![[thumbnail of LoA 944 Nanda.pdf]](/style/images/fileicons/application_pdf.png) |
PDF
LoA 944 Nanda.pdf Download (264kB) |
![[thumbnail of 944+sent+to+reviewer.docx]](/style/images/fileicons/text_html.png) |
HTML
944+sent+to+reviewer.docx Download (2MB) |
Abstract
Evans syndrome is a rare autoimmune disorder characterized by the simultaneous or sequential occurrence of autoimmune hemolytic anemia (AIHA) and immune thrombocytopenic purpura (ITP), and sometimes accompanied by autoimmune neutropenia. The complexity of this syndrome poses significant challenges in diagnosis and therapeutic management, given its chronic, heterogeneous course, and the varying responses of patients to treatment. This narrative review aims to provide a comprehensive overview of diagnostic approaches and current therapeutic options for patients with Evans syndrome. Literature search methods were conducted using the PubMed and Science Direct databases with relevant keywords up to 2025, as well as reviewing references from related articles. The study findings indicate that there is no widely accepted standard protocol for managing Evans syndrome. First-line therapy typically involves steroids and/or IVIG, while second-line therapy includes rituximab, immunosuppressive agents, and thrombopoietin receptor agonists. In severe or refractory cases, splenectomy, biological therapy, or stem cell transplantation may be considered. In conclusion, the management of Evans syndrome is individualized and still heavily dependent on clinical experience and indirect evidence from AIHA and isolated ITP therapy. Further research is needed to develop more specific and evidence-based treatment protocols for Evans syndrome
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | Evans syndrome, Autoimmune Hemolytic Anemia (AIHA), Immune Thrombocytopenic Purpura (ITP), Management Therapy |
| Subjects: | R Medicine > RS Pharmacy and materia medica |
| Divisions: | Postgraduate Programs > Master Program in Clinical Pharmacy |
| Depositing User: | Ester Sri W. 196039 |
| Date Deposited: | 05 Aug 2025 07:24 |
| Last Modified: | 05 Aug 2025 07:24 |
| URI: | http://repository.ubaya.ac.id/id/eprint/49314 |
Actions (login required)
 |
View Item |
